Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in PNH
NCT02598583Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoint: Percent Change In Lactate Dehydrogenase Levels at Day 169. Started Nov 2015; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02598583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598583.